AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17298707 — intervention group
Group type: EXPERIMENTAL
Intervention: SYN1 (spray‐dried mixture of chicory oligofructose and long‐chain inulin)
Number of subjects: 15
Study 17298707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15185885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB)
Number of subjects: 50
Study 15185885 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Transluminal Coronary Angioplasty (PTCA)
Number of subjects: 50
Study 11930971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track preventive intervention
Number of subjects: 0
Study 9514453 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg/day
Number of subjects: 2100
Study 9514453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2100
Study 7698708 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (3 x 100 micrograms/day subcutaneously)
Number of subjects: 10
Study 7698708 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 x 0.9% saline solution subcutaneously)
Number of subjects: 10
Study 2720457 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Z Derm dressing
Number of subjects: 32
Study 2720457 — intervention group
Group type: COMPARATOR
Intervention: Jelonet dressing
Number of subjects: 32
Study 335793 — intervention group
Group type: COMPARATOR
Intervention: p.o. acenocoumarin (control)
Number of subjects: 313
Study 335793 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. heparin alone
Number of subjects: 313
Study 335793 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. heparin + p.o. acenocoumarin
Number of subjects: 313
Study 335793 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. heparin (5000 IU twice daily)
Number of subjects: 313
Study 31480245 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds
Number of subjects: 42
Study 31480245 — intervention group
Group type: COMPARATOR
Intervention: Savoury crackers
Number of subjects: 42
Study 31480245 — intervention group
Group type: COMPARATOR
Intervention: Water (zero energy control)
Number of subjects: 42
Study 29031393 — intervention group
Group type: EXPERIMENTAL
Intervention: FO group (400mL/day of fish oil-enriched dairy drink with 320mg DHA + 72mg EPA)
Number of subjects: 46
Study 29031393 — intervention group
Group type: COMPARATOR
Intervention: CT group (400mL/day of non-supplemented dairy drink)
Number of subjects: 46
Study 29031393 — intervention group
Group type: EXPERIMENTAL
Intervention: FO group
Number of subjects: 46
Study 25833163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenAC vaccine (administered in 2-dose series for 6-23 months and single dose for 2-5 years)
Number of subjects: 1200
Study 25833163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenAC vaccine
Number of subjects: 1200
Study 25833163 — intervention group
Group type: COMPARATOR
Intervention: Licensed vaccines (control group)
Number of subjects: 1200
Study 23536104 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose drink
Number of subjects: 35
Study 23536104 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 35
Study 22056152 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) and radiation therapy (RT) (65‐69 Gy to the prostate and seminal vesicles, 45 Gy to the pelvic nodes)
Number of subjects: 1205
Study 22056152 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) only
Number of subjects: 1205
Study 22056152 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) and radiation therapy (RT)
Number of subjects: 1205
Study 19336625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro mix 75/25 (LM75/25)
Number of subjects: 2041
Study 16491367 — intervention group
Group type: EXPERIMENTAL
Intervention: oestradiol/dydrogesterone
Number of subjects: 193
Study 16491367 — intervention group
Group type: COMPARATOR
Intervention: CEE/norgestrel
Number of subjects: 193
Study 15488342 — intervention group
Group type: EXPERIMENTAL
Intervention: METH+/MJ- (n=26)
Number of subjects: 94
Study 15488342 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 94
Study 15488342 — intervention group
Group type: EXPERIMENTAL
Intervention: METH+/MJ+ (n=27)
Number of subjects: 94
Study 11009745 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-comparison feedback (physician 'report cards')
Number of subjects: 48
Study 11009745 — intervention group
Group type: COMPARATOR
Intervention: General information about monitoring functional status (Control)
Number of subjects: 48
Study 8979644 — intervention group
Group type: EXPERIMENTAL
Intervention: PM exercise (16:00 hrs)
Number of subjects: 24
Study 2004261 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation in healthy subjects
Number of subjects: 22
Study 2004261 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation in patients with MS
Number of subjects: 22
Study 7130340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 7130340 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose estrogen (1/0.5 mg)
Number of subjects: 92
Study 7130340 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose estrogen (2/1 mg)
Number of subjects: 92
Study 7130340 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose estrogen (4/2 mg)
Number of subjects: 92
Study 7130340 — intervention group
Group type: EXPERIMENTAL
Intervention: All hormone groups (low, medium, high)
Number of subjects: 92
Study 7130340 — intervention group
Group type: COMPARATOR
Intervention: Untreated postmenopausal women
Number of subjects: 92
Study 7130340 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment values of S-aPh and U-HyPro
Number of subjects: 92
Study 30798000 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU per day vitamin D supplementation
Number of subjects: 140
Study 30798000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 28214948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiix-warfarin patients
Number of subjects: 1143
Study 28214948 — intervention group
Group type: COMPARATOR
Intervention: PT-warfarin patients
Number of subjects: 1143
Study 26526494 — intervention group
Group type: EXPERIMENTAL
Intervention: High fidelity simulation (SimNewB)
Number of subjects: 101
Study 26526494 — intervention group
Group type: COMPARATOR
Intervention: Low fidelity simulation (Resusci(®) Baby Basic)
Number of subjects: 101
Study 24676313 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day of Zn for 6 months
Number of subjects: 108
Study 24676313 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day of Zn for 6 months
Number of subjects: 108
Study 24676313 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 108
Study 22554019 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% liquid lidocaine on cotton swabs
Number of subjects: 50
Study 22554019 — intervention group
Group type: COMPARATOR
Intervention: 3.5% lidocaine gel
Number of subjects: 50
Study 20441720 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine in extensive metabolizers (EMs)
Number of subjects: 0
Study 20441720 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine in poor metabolizers (PMs)
Number of subjects: 0
Study 20441720 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 17920374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esmolol (beta(1) blockade)
Number of subjects: 14
Study 17920374 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 14
Study 16135174 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose regimen
Number of subjects: 69
Study 16135174 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable dose regimen
Number of subjects: 69
Study 11755936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg per oral)
Number of subjects: 12
Study 11755936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10075094 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (8 microg/kg birthweight/day)
Number of subjects: 200
Study 10075094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 7484325 — intervention group
Group type: EXPERIMENTAL
Intervention: Two scales based on the Fagerstrom Tolerance Questionnaire
Number of subjects: 0
Study 7484325 — intervention group
Group type: EXPERIMENTAL
Intervention: Two subsets of three items from each scale
Number of subjects: 0
Study 7484325 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports of using smokeless tobacco within 30 min of waking
Number of subjects: 0
Study 2913252 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracycline used as a suspension in a gelatin sponge placed in the sockets of extracted mandibular third molars.
Number of subjects: 0
Study 2913252 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 0
Study 1093426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam 10 mg
Number of subjects: 0
Study 1093426 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular diazepam 10 mg
Number of subjects: 0
Study 1093426 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral and intramuscular diazepam
Number of subjects: 0
Study 1093426 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 0
Study 30137250 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 participants with TB coinfection
Number of subjects: 860
Study 28860395 — intervention group
Group type: EXPERIMENTAL
Intervention: Closing wedge high tibial osteotomy (HTO)
Number of subjects: 70
Study 28860395 — intervention group
Group type: COMPARATOR
Intervention: Opening wedge high tibial osteotomy (HTO)
Number of subjects: 70
Study 26032346 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed brassiere straps
Number of subjects: 15
Study 26032346 — intervention group
Group type: COMPARATOR
Intervention: Parallel brassiere straps
Number of subjects: 15
Study 23560884 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (2 μg/kg)
Number of subjects: 30
Study 23560884 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (2 μg/kg)
Number of subjects: 30
Study 23560884 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 30
Study 23560884 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 30
Study 21194181 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HRT
Number of subjects: 76
Study 21194181 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 76
Study 21194181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 76
Study 19929258 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cultured BM-derived MSCs along with standard wound dressing
Number of subjects: 24
Study 19929258 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing regimen
Number of subjects: 24
Study 21610662 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX-based probabilities calculated without BMD
Number of subjects: 1608
Study 21610662 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX-based probabilities calculated with BMD
Number of subjects: 1608
Study 21610662 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with a prior fragility fracture
Number of subjects: 1608
Study 21610662 — intervention group
Group type: EXPERIMENTAL
Intervention: Criterion A (BMD T-score of -2.5)
Number of subjects: 1608
Study 21610662 — intervention group
Group type: EXPERIMENTAL
Intervention: Criterion D (prior fracture plus fixed threshold)
Number of subjects: 1608
Study 21610662 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria B and C (age-dependent threshold)
Number of subjects: 1608
Study 21610662 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria B and C
Number of subjects: 1608
Study 21610662 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria A and D
Number of subjects: 1608
Study 16020071 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 24
Study 16020071 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 12512928 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg oral misoprostol every 3 hours
Number of subjects: 0
Study 12512928 — intervention group
Group type: COMPARATOR
Intervention: 100 microg oral misoprostol every 6 hours
Number of subjects: 0
Study 10335039 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (recombinant human growth hormone) administered daily subcutaneously for 12 months, initial dose 0.125 IU/kg b.w./week, adjusted to maintain serum IGF-1 levels of 280-350 micrograms/L.
Number of subjects: 18
Study 7856175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 715
Study 7856175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day
Number of subjects: 715
Study 7856175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 715
Study 2688475 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia
Number of subjects: 381
Study 2688475 — intervention group
Group type: COMPARATOR
Intervention: Intermittent epidural analgesia
Number of subjects: 381
Study 4569549 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E(2) infused simultaneously with oxytocin
Number of subjects: 20
Study 4569549 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (Syntocinon) administered in escalating doses
Number of subjects: 20
Study 11392598 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (100 microg intravaginally every 4 h)
Number of subjects: 360
Study 11392598 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (by intravenous infusion)
Number of subjects: 360
Study 31183444 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 lymph node dissection
Number of subjects: 768
Study 31183444 — intervention group
Group type: COMPARATOR
Intervention: D2 lymph node dissection
Number of subjects: 768
Study 29316130 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 761
Study 29316130 — intervention group
Group type: COMPARATOR
Intervention: IAsp
Number of subjects: 761
Study 27434834 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-affected group
Number of subjects: 79
Study 27434834 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from families with a surviving grandparent with HIV
Number of subjects: 79
Study 27434834 — intervention group
Group type: COMPARATOR
Intervention: Family-based, cognitive-behavioral HIV intervention
Number of subjects: 79
Study 25185483 — intervention group
Group type: EXPERIMENTAL
Intervention: Federal audits
Number of subjects: 85
Study 25185483 — intervention group
Group type: EXPERIMENTAL
Intervention: State audits
Number of subjects: 85
Study 25185483 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no audits)
Number of subjects: 85
Study 22580944 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 12
Study 22580944 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte 148
Number of subjects: 12
Study 20399212 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (200 mg)
Number of subjects: 18
Study 20399212 — intervention group
Group type: COMPARATOR
Intervention: Placebo progesterone
Number of subjects: 18
Study 17654043 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of l-arginine and 75 mg of acetylsalicylic acid daily for 20 days
Number of subjects: 0
Study 17654043 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnancy
Number of subjects: 0
Study 15890494 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity stimuli
Number of subjects: 6
Study 15890494 — intervention group
Group type: EXPERIMENTAL
Intervention: Invalid cues
Number of subjects: 6
Study 15890494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue validity effects
Number of subjects: 6
Study 15890494 — intervention group
Group type: EXPERIMENTAL
Intervention: Evoked electric potential
Number of subjects: 6
Study 11796357 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (35, 50, or 70 mg)
Number of subjects: 140
Study 11796357 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (0.5 mg/kg)
Number of subjects: 140
Study 11796357 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (any dose)
Number of subjects: 140
Study 9787370 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 463
Study 9787370 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 463
Study 7658946 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% of the lactic acidosis threshold (LAT)
Number of subjects: 27
Study 7658946 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% delta
Number of subjects: 27
Study 7658946 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% delta
Number of subjects: 27
Study 7658946 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% delta
Number of subjects: 27
Study 2698943 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 36
Study 2698943 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 36
Study 2698943 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide + amiloride
Number of subjects: 36
Study 2698943 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 184912 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT) added to 15 months' maintenance actinomycin D (AMD) in Gp I patients under 2 years of age
Number of subjects: 606
Study 184912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined actinomycin D (AMD) and vincristine (VCR)
Number of subjects: 606
Study 184912 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative vincristine (VCR) in Gp IV patients
Number of subjects: 606
Study 184912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postoperative RT) in Gp I patients under 2 years of age
Number of subjects: 606
Study 30843046 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 264
Study 30843046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 30939487 — intervention group
Group type: EXPERIMENTAL
Intervention: COLM‐SST (25 mg of caraway oil and 20.75 mg of L‐menthol per capsule, at 2 capsules per dose, twice per day)
Number of subjects: 95
Study 30939487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 28577848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryothermal energy only (group 1)
Number of subjects: 709
Study 28577848 — intervention group
Group type: COMPARATOR
Intervention: Combination of cryothermal and bipolar radiofrequency (group 2)
Number of subjects: 709
Study 25521219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic FFP
Number of subjects: 81
Study 25521219 — intervention group
Group type: COMPARATOR
Intervention: Reactive FFP
Number of subjects: 81
Study 23891420 — intervention group
Group type: COMPARATOR
Intervention: CDC Control
Number of subjects: 125
Study 23891420 — intervention group
Group type: EXPERIMENTAL
Intervention: Facts Only
Number of subjects: 125
Study 23891420 — intervention group
Group type: EXPERIMENTAL
Intervention: Facts and Myths
Number of subjects: 125
Study 23891420 — intervention group
Group type: EXPERIMENTAL
Intervention: Facts, Myths, and Refutations
Number of subjects: 125
Study 23891420 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 125
Study 20805005 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (400 mcg/d) + vitamin B12 (100 mcg/d) supplementation
Number of subjects: 900
Study 20805005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 19878827 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification under vacuum of 250 mm Hg (subgroup 1)
Number of subjects: 998
Study 19878827 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification under vacuum of 450 mm Hg (subgroup 2)
Number of subjects: 998
Study 19878827 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification under vacuum of 600 mm Hg (subgroup 3)
Number of subjects: 998
Study 16525137 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg once daily for 52 weeks
Number of subjects: 715
Study 16525137 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg once daily for 52 weeks
Number of subjects: 715
Study 12694427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing chlorhexidine (0.05%), cetylpyridinium chloride (0.05%), and zinc-lactate (0.14%)
Number of subjects: 40
Study 12694427 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse without active ingredients
Number of subjects: 40
Study 10809816 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) in combination with cyclosporin and prednisone (MMF+)
Number of subjects: 84
Study 10809816 — intervention group
Group type: COMPARATOR
Intervention: Cylosporin and prednisone (MMF-)
Number of subjects: 84
Study 8852484 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3 g/day with triglyceride preparation; 7.7 g/day with ethyl-ester preparation)
Number of subjects: 8
Study 1537778 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 30
Study 1537778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6391667 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid given seven times a day combined with 600 mg BID of cimetidine (C + A7)
Number of subjects: 8
Study 6391667 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid given four times a day combined with cimetidine BID (C + A4)
Number of subjects: 8
Study 6391667 — intervention group
Group type: COMPARATOR
Intervention: Antacid alone seven times daily (A7)
Number of subjects: 8
Study 6391667 — intervention group
Group type: COMPARATOR
Intervention: All active treatments (C + A7, C + A4, A7) compared to placebo
Number of subjects: 8
Study 6391667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine morning dose
Number of subjects: 8